A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
Eli Lilly and Company
1,100 participants
Oct 15, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered SC
Administered SC
Locations(123)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07219966